Free Newsletter
PhRMA: Market overreacted to Obama plans
Free newsletter via e-mail
Tools
In another layer of support for President Obama's healthcare reform plans, PhRMA chief Billy Tauzin said drug companies won't lose even if universal healthcare ends up depressing pharma prices. That's because drugmakers would sell more of the lower-priced meds, making up in volume what they lose on price cuts. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: